Tesaro Adds Runway By Out-licensing Niraparib In Prostate Cancer
This article was originally published in Scrip
Deriving income from letting somebody else pursue a direction you weren't prioritizing is always a good business strategy, which is what Tesaro Inc. did by out-licensing niraparib in prostate cancer to Janssen Biotech Inc. while retaining all other rights to the poly ADP-ribose polymerase (PARP) inhibitor.
You may also be interested in...
Now in confidential talks with Sanofi and other buyout suitors, Medivation hopes to increase offers on the basis of its PARP inhibitor's dual-mechanism promise.
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.
Execs from Madrigal, Cirius and Axcella say the FDA’s complete response letter is specific to shortcomings of Intercept’s OCA – and leaves the race to be first to market wide open again.